Preliminary Program

Programme-at-a-Glance

Monday, October 13th 2008

Back To Top
16:00 - 18:00 Opening Ceremony
Auditorium 1 Chairs: Lynn Morris, Glenda Gray, Koleka Mlisana, Carolyn Williamson
Sizophila Choir
Welcome and Opening Remarks
Lynn Morris
South Africa's Commitment to AIDS Vaccine Development
Honourable Minister Ms Barbara Hogan
Scientific Innovation and the Path to an AIDS Vaccine
Deputy Minister Mr Derek Hanekom
What Challenges/Opportunities Face African Scientists in the Development of an HIV Vaccine?
Malegapuru Makgoba
HIV Vaccine Research and the Global HIV Vaccine Enterprise
Alan Bernstein
Sang-froid in a Time of Trouble
Stanley A Plotkin
18:00 Welcome Reception

Tuesday, October 14th 2008

Back To Top
08:30 – 10:00 Plenary Session 01
Chairs: Nelson Michael and Alash’le Abimiku
08:30 – 09:00 Vaccine-Induced Immunity in T-Cell Based Candidate HIV Vaccines
M Juliana McElrath
09:00 – 09:30 Community Issues Relating to Prevention Research in Developing Countries
Pedro Goicochea
09:30 – 10:00 Antibody Protection in the Macaque Model
Dennis R Burton
10:00 – 10:30 Tea/Coffee Break
10:30 - 12:30 Parallel Oral Abstract Session 01
HIV Transmission and Acute HIV Infection
Jesus F. Salazar-Gonzalez
Debrah L. Boeras
Gama P Bandawe
Qinxue Hu
Catherine M Card
Michael K Liu
Hanneke Schuitemaker
Hendrik Streeck NIA Winner


10:30 - 12:30

Parallel Oral Abstract Session 02
T Cell Vaccines and Animal Models
Brad R Jones NIA Winner
Fiona Tanzer
David A Garber
Tomas Hanke
R Keith Reeves
Christiane Stahl-Hennig
Meritxell Genescà Ferrer
Rajeev Gautam


10:30 - 12:30

Parallel Oral Abstract Session 03
Neutralizing Antibodies and Immune Escape
Lautaro Gabriel Perez
Xiang-Peng Kong
Dimiter S Dimitrov
Penny L Moore NIA Winner
Marta Massanella
M Anthony Moody
David Davis
Shiu-Lok Hu
12:30 – 14:30 Lunch
13:00 - 13:30 Keynote Lecture
Chair: Anthony Mbewu
HIV Vaccines: Science and Policy
Anthony S Fauci
13:30 - 14:30

Parallel Poster Discussion Group 01
The Sway of Host Genetic Factors

Parallel Poster Discussion Group 02
Navigating the Landscape of Clinical

Parallel Poster Discussion Group 03
HIV: A Moving Target

Parallel Poster Discussion Group 04
Managing Challenges Every Step of the Way
14:30 -15:30 Parallel Special Session 01
Preparing for Future Efficacy Trials
Moderators: Glenda Gray and Barney Graham
HIV Vaccine Development in the Post STEP/Phambili Era
Lawrence Corey
Learning from the Past: How Prepared are we for Future HIV Vaccine Efficacy Trials in Uganda?
Pontiano Kaleebu
Reassessing the Screening Test of Concept (STOC) Trial Design for AIDS Vaccines
Frances Priddy
Vaccine Efficacy Trial Design Considerations in a Post-STEP Era
Steve Self
Regulatory Considerations for Future Efficacy Trials
Helen Rees


14:30 -15:30

Parallel Oral Abstract Session 04
Immune Responses at Mucosal Sites
Alfred Bere
Mario Roederer
Pamela A Kozlowski
David JM Lewis
14:30 -15:30 Parallel Special Session 02
Innovations in AIDS Vaccine Discovery
Moderator: Wayne Koff
Reverse Immunization: A Novel Strategy for In Vivo HIV Neutralization
K Reed Clark
Engineering a Human Immune System In Vitro for Rapid Vaccine Evaluation
William L Warren
Immune Complexes as HIV-1 Vaccine Candidate
Sanjay Phogat
Toward a Chimeric Live Attenuated Vaccine for Human Immunodeficiency Virus
Clayton Beard
15:30 – 16:00 Tea/Coffee Break
16:00 – 18:00 Parallel Debate 01
Should Animal Models be a Gatekeeper for Human Clinical Trials?
Moderator: Margaret (Peggy) Johnston
Yes Team: R Paul Johnson and Jeffrey D Lifson
No Team: David Weiner and Jerald C Sadoff
16:00 – 16:15 Yes Team Opening Statement
16:15 – 16:30 No Team Opening Statement
16:30 – 17:00 Rebuttals (Both Teams)
17:00 – 17:50 Audience Questions and Comments
17:50 – 18:00 Final Comments
16:00 – 18:00 Parallel Symposium 01:
The Search for New and More Broadly Neutralizing Antibodies
Moderators: John Mascola and James Robinson
16:00 – 16:20 Profiling the Specificity of Neutralizing Activity in a Panel of HIV+ Plasmas from Subtypes B and C Chronic Infections
James Binley
16:20 – 16:40 The Search for New Broadly Neutralizing Antibodies and Methods of their Induction: Finding a Path to Successful HIV-1 Vaccine Development
Barton F Haynes
16:40 – 17:00 Frequency and Phenotype of HIV Envelope-specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies
Mark Connors
17:00 – 17:20 Novel Neutralizing Monoclonal Antibodies to HIV-1 Derived from Humans and Llamas
Robin Weiss
17:20 – 17:40 A Panel of HIV-1 Neutralizing Antibodies Isolated from Non-clade B HIV-1 Infected Donors
Davide Corti
17:40 – 18:00 Search for Broadly Neutralizing Antibodies against HIV Using a Single Cell Approach
Richard Wyatt
18:00 Gala Dinner at Moyo, Spier Wine Estate, Stellenbosch

Wednesday, October 15th 2008

Back To Top
08:30 - 10:00 Plenary Session 02
Chairs: Brigitte Autran and Seth Berkley
08:30 – 09:00 Correlates of Protective Vaccine Induced T Cell Immunity
Bruce D Walker
09:00 – 09:30 Emerging Ethical Issues in Preventative HIV Vaccinne Research
Ruth Macklin
09:30 – 10:00 HIV Vaccine Efficacy Trials: Past, Present and Future
Susan Buchbinder
10:30 - 12:30 Parallel Oral Abstract Session 05
Updates on Clinical Trials
George N Pavlakis
Eva Van Braeckel
Stephen C De Rosa
Samuel O Pine
Muhammad Bakari
Mary Marovich
Gavin J Churchyard
Punnee Pitisuttithum


10:30 - 12:30

Parallel Oral Abstract Session 06
Cellular Immunity and Escape
Pholo W Maenetje
Alexandre Harari
Florencia Pereyra
Guido Ferrari
Margaret E Feeney
Julia G Prado
Jonathan Carlson
Yaoyu E Wang


10:30 - 12:30

Parallel Oral Abstract Session 07
Novel Enevelope Immunogens
Donald Van Ryk
D Cameron Dunlop
Yu Geng
Mark Melchers
Michael Cho
S Munir Alam
Gilad Ofek
T Matt Holl
12:30 – 13:30 Lunch
13:30 - 15:30 Parallel Oral Abstract Session 08
A Delicate Balancing Act: Vulnerability and Safeguards
Simon Sigirenda
Paula M Frew
Janan Dietrich
Heather B Jaspan
Kayitesi Kayitenkore
Peter A Newman
Gabriela Calazans
Kimberly K Louis
13:30 – 15:30 Parallel Debate 02
Should there be Further Large Scale Efficacy Testing of T-Cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Moderator: John Moore
13:30 – 14:20

Should there be Further Efficacy Testing of T-Cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Gary J Nabel

Antibodies and T Cells: Horses for Courses
Dennis R Burton

We should still Test T Cell Based Vaccines
David Watkins

An Analysis of HIV Vaccine Efforts
Robert C Gallo
14:20 – 14:40 Rebuttal Phase
14:40 – 15:30 Final Comments and Questions
13:30 - 15:30 Parallel Oral Abstract Session 09
No Time for Recall: Innate Immune Responses
Daniel E Zak NIA Winner
Steven E Bosinger NIA Winner
Erica Andersen-Nissen
Galit Alter
Amy Chung
William H Carr
Aida Sivro
Jinghe Huang
15:30 – 16:00 Tea and Coffee Break
16:00 – 18:00 Parallel Round Table 01
Converging of Prevention Technologies
Moderators: Mitchell Warren and Helen Rees
16:00 – 16:20 Can Vaccines And Microbicides be Co-developed?
John Moore
16:20 – 16:40 Antiretroviral Prophylaxis: A Point of Convergence in the Scientific Agendas for Pre- and Post-exposure Prophylaxis, Microbicides and Perinatal HIV Prevention
Salim Abdool Karim
16:40 – 17:00 Mechanism of HIV Entry into the Squamous Epithelium of the Female Genital Tract
Tom J Hope
17:00 – 17:20 Vaccines and Microbicides? Getting the Best out of New Prevention Technology
Robin Shattock
17:20 – 17:40 Prevention Research Efforts in Cape Town
Linda-Gail Bekker
17:40 – 18:00 HIV Prevention: Designing and Re-Designing HIV Vaccine Clinical Trials
Magdalena E Sobieszczyk
16:00 – 18:00 Parallel Symposium 02
Systems Biology to Unravel and Decipher the Interface between Innate and Adaptive Immunity
Moderators: Alan Aderem and Clive Gray
16:00 – 16:20 Population Diversity in HIV-Associated Genes: Consequences and Cautions
Cheryl Winkler
16:20 – 16:40 Plasmacytoid Dendritic Cells in Lymphoid Organs: Comparative Studies at the Interface Between Innate and Adaptive Immunity Against HIV
Anne Hosmalin
16:40 – 17:00 HIV and Synapses
Olivier Schwartz
17:00 – 17:20 Genetically Determined Differences in NK Cell Function in HIV-1 Infection
Marcus Altfeld
17:20 – 17:40 Systems Biology approaches Predict the Immunogenicity of the Yellow Fever Vaccine-17D in Humans
Bali Pulendran
17:40 – 18:00 A Systems Approach to Dissecting Immunity
Alan Aderem
16:00 – 18:00 Parallel Symposium 03
Biology of Vectors / Next Generation Vaccine Vectors
Moderators: Dan H Barouch and Anna-Lise Williamson
16:00 – 16:20 Induction of Potent T Cell Immunity in Macaques by EP DNA + Molecular Adjuvants
David Weiner
16:20 – 16:40 Live Attenuated Measles Virus Vaccine Vector: Challenges and Prospectives
Hussein Y Naim
16:40 – 17:00 Novel Adenovirus Vector-Based Vaccines for HIV-1
Dan H Barouch
17:00 – 17:20 Can Effector-Memory T Cell Responses Contribute to AIDS Vaccine Efficacy?
Louis Picker
17:20 – 17:40 A Comparative Analysis of Toll-like Receptor Ligands as Vaccine Adjuvants with SIV Gag Protein in Non-human Primates
Robert Seder
17:40 – 18:00 Novel HIV Vaccines for Southern Africa
Anna-Lise Williamson
18:00 – 20:00 Poster Session

Thursday, 16 October 2008

Back To Top
08:30 -10:00 Plenary Session 03
Chairs: Jack Whitescarver and Nina Russell
08:30 – 09:00 A New Look at the Transmitted Virus and its Source in the Genital Tract
Ronald Swanstrom
09:00 – 09:30 HIV Prevention: in Search of a Future
James McIntyre
09:30 – 10:00 Mucosal Immunity in HIV and SIV Infection
Guido Silvestri
10:00 – 10:30 Tea and Coffee Break
10:30 – 12:15 Late Breaker Session
Chairs: Joep Lange and Richard A Koup

Holly Janes
Glenda Gray
Nicole Frahm
Nancy Wilson
Yiming Shao
Gnana Gnanakaran
Robert Pejchal
Gary Nabel
M Anthony Moody
Caroline Tiemessen
12:15 – 13:15 Rapporteur Session
Chairs: Lynn Morris and Yves Levy
Vaccine Concepts and Design
Edward Rybicki
T Cell Immunology and Innate Immunity
Galit Alter
B Cell Immunology, Neutralizing Antibodies and Mucosal Immunology
Ralph Pantophlet
Clinical Trials
Jintanat Ananworanich
13:15 – 13:30 Closing and Handover
Chair: Lynn Morris
AIDS Vaccine 2009
Yves Lévy
All Content ©2005 - 2009 Global HIV Vaccine Enterprise